Professor Katherine Payne PhD, MSc, DipClinPharm, BPharm, MRPharmS

2012

• Shabaruddin F & Payne K. (2012). Cost-effectiveness of Pharmacogenomics in clinical practice. Personalized Medicine: Advances in Nanotechnology,Drug Delivery and Therapy. eScholarID:133557

2011

• Callard A, Payne K, Newman WG. (In-press). Delivering a pharmacogenetic service in the NHS: is there a role for genetic counsellors? Journal of Genetic Counselling, eScholarID:133553
• Daker-White G, Sanders C, Greenfield J, Ealing J, Payne K. (2011). Getting a diagnosis versus learning to live with it? The case of the progressive ataxias. Chronic Illness, 7(2), 120-133. eScholarID:133552 | DOI:10.1177/1742395310390532
• Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T. (2011). The clinical and cost effectiveness of genotyping for CYP2D6 for the management of women with breast cancer. Health Technology Assessment, 15(33), 1-102. eScholarID:133555 | DOI:10.3310/hta15330
• Newman W, Payne K, Tricker K, Roberts SA, Fargher EA, Pushkapom S, Alder JE, Sidgwick GP, Payne D, Elliott RA, Elles R, Ramsden SC, Andrews J, Houston JB, Qasim F, Shaffer J, Griffiths CE, Ray D, Bruce I, TARGET study recruitment team, Ollier WE. (2011). A pragmatic randomised controlled trial of thiopurine methyltransferase (TPMT) genotyping in the management of patients, prior to azathioprine treatment: The TARGET study. Pharmacogenomics, 12(6), 815-826. eScholarID:133556 | DOI:DOI:10.2217/pgs.11.32
• Payne K, Fargher EA, Roberts S, Tricker K, Elliott RA, Ratcliffe J, Newman WG. (2011). Valuing pharmacogenetic testing services: A comparison of patients’ and healthcare professionals’ preferences. Value in Health, 14(1), 121-134. eScholarID:133549 | DOI:doi:10.1016/j.jval.2010.10.007
• Prosser LA, Payne K, Rusinak D, Shi P, Uyeki T, Messonnier M. (2011). Valuing Health Across the Lifespan: Health State Preferences for Seasonal Influenza Illnesses in Patients of Different Ages. Value in Health, 14(1), 135-143. eScholarID:133551 | DOI:doi:10.1016/j.jval.2010.10.026
• Sullivan WG & Payne K. (2011). The Appropriate Elicitation of Expert Opinion in Economic Models: Making Expert Data Fit for Purpose. Pharmacoeconomics, 29(6), 455-459. eScholarID:133554

2010

• Payne K. (2010). Economics of cancer pharmacogenetics. In Newman WG (Ed.), Pharmacogenetics: making cancer treatment safer and more effective. Springer. eScholarID:133561
• Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, De Warren-Penny P & Dickson R. (2010). The clinical and cost effectiveness of testing for cytochrome P450 polymorphisms in patients treated with antipsychotics. Health Technol Assess 2010; 14(3): 1-182. Health Technology Assessment, 14(3), 1-182. eScholarID:117099 | DOI:DOI.10.3310/hta14030
• Higgs J, Payne K, Roberts C, Newman WG. (2010). Thiopurine s-methyltransferase (TPMT) testing to identify patients at risk of myelosuppression due to thiopurine drugs: a systematic review and meta-analysis. Pharmacogenomics, 11(2), 163-175. eScholarID:117068
• Shabbaruddin F, Elliott RA, Newman WG, Payne K. (2010). Understanding treatment pathways and clinical management of chemotherapy patients using critical evidence synthesis and a survey of clinical experts: Towards an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan. British Journal of Cancer, 103(3), 315-323. eScholarID:117021 | DOI:doi:10.1038/sj.bjc.6605766
• Payne K & Gurwitz D. (2010). Informing Resource Allocation Decision-making: The Economic Evaluations of Pharmacogenetic Tests. Drug Development Research, 71(8), 445-448. eScholarID:133559
• Shabaruddin FH, Elliott RA, Valle JW, Newman WG and Payne K. (2010). Reply: Guesstimates are not good enough for determining what is happening in routine care. British Journal of Cancer, eScholarID:133560

2009

• Prosser L & Payne K. (2009). Discrete choice. In Kattan MW (Ed.), Encyclopedia of Medical Decision Making. Thousand Oaks, CA: Sage. eScholarID:133562
• David Gurtwitz, C Rodríguez-Antona, Payne K, Newman WW.G, JP Gisbert, E Gutiérrez de Mesa, D Ibarreta. (2009). Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. European Journal of Human Genetics, eScholarID:1d21285 | DOI:10.1038/ejhg.2009.10
• Gidman W, Day J, Hassell K, Payne K. (2009). Delivering health care through community pharmacies: are working conditions deterring female pharmacists' participation? J Health Serv Res Policy, 14( 3), 141-9. eScholarID:1d19310 | DOI:10.1258/jhsrp.2009.008077
• Higgs JE, Andrews J, Gurwitz D, Payne K, Newman W. (2009). Pharmacogenetics education in British medical schools. Genomic Med, eScholarID:1d19003 | DOI:10.1007/s11568-009-9032-6
• Payne K, Newman WW.G, Gurwitz D, Ibaretta D, Phillips KA. (2009). TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Personalized Medicine, 6, 103-113. eScholarID:1d21290 | DOI:10.2217/17410541.6.1.103
• Payne K. (2009). Fish and chips all round? Regulation of genetic-based technologies. Health Economics, 18(11), 1233-1236. eScholarID:117047 | DOI:10.1002/hec.1553

2008

• Grosse S, Wordsworth S, Payne K. (2008). Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med, 10( 9), 648-54. eScholarID:1d32482 | DOI:10.1097/GIM.0b013e3181837217
• McAllister M, Payne K, Macleod R, Nicholls S, Donnai D, Davies L. (2008). What process attributes of clinical genetics services could maximise patient benefits? Eur J Hum Genet, eScholarID:1d32161
• McAllister MM, Payne K, Macleod R, Nicholls S, Dian Donnai, Davies LM. (2008). Patient empowerment in clinical genetics services. J Health Psychol, 13( 7), 895-905. eScholarID:1d17863 | DOI:10.1177/1359105308095063
• Moore JK, Elliott RA, Payne K, Payne K, Moore EW, St Leger AS, Harper NJ, Pollard BJ, Kerr J. (2008). The effect of anaesthetic agents on induction, recovery and patient preferences in adult day case surgery: a 7-day follow-up randomized controlled trial. Eur J Anaesthesiol, 1-8. eScholarID:1d17408
• Newman WW.G, Payne K. (2008). Removing barriers to a clinical pharmacogenetics service. Personalized Medicine, 5, 471-480. eScholarID:1d21292 | DOI:10.2217/17410541.5.5.471
• Payne K, Nicholls S, McAllister M, Macleod R, Donnai D, Davies L. (2008). Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health, 11( 3), eScholarID:1d32078 | DOI:DOI: 10.1111/j.1524-4733.2007.00259.x
• Payne K, Stuart Nicholls, McAllister MM, Macleod R, Donnai D, Davies LM. (2008). Outcome measurement in clinical genetics services: a systematic review of validated measures. Value in Health, 11(3), 497-508. eScholarID:1d17869 | DOI:10.1111/j.1524-4733.2007.00259.x
• Payne K. (2008). Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key. Pharmacogenomics, 9( 1), 1-4. eScholarID:1d31959

2007

• Gidman WK, Day JM, Hassell K, Payne K. (2007). Pay not a priority: an application of Q Methodology to a female workforce question. eScholarID:2d1948
• Fargher E, Eddy C, Newman W, Qasim F, Tricker K, Elliott R, Payne K. (2007). Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics, 8( 11), 1511-9. eScholarID:1d32462
• Fargher E, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce IN, Payne K. (2007). Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther, 32( 2), 187-95. eScholarID:1d15565
• Gidman W, Elliott R, Payne K, Meakin G, Moore J. (2007). A comparison of parents and pediatric anesthesiologists' preferences for attributes of child daycase surgery: a discrete choice experiment. Paediatr Anaesth, 17( 11), 1043-52. eScholarID:1d32360
• Gidman W, Hassell K, Day J, Payne K. (2007). The impact of increasing workloads and role expansion on female community pharmacists in the United Kingdom. Res Social Adm Pharm, 3( 3), eScholarID:1d31960
• Gidman W.K, Hassell K, Day JM, Payne K. (2007). The impact of increasing workloads and role expansion on female community pharmacists in the United Kingdom. Research in Social and Administrative Pharmacy, 3, 285-302. eScholarID:1d28106
• Gidman W.K, Hassell K, Day JM, Payne K. (2007). The impact of mandatory continuous professional development and training to deliver the new contract on female community pharmacists: A qualitative study. Pharmacy Education, 7[3], eScholarID:1d27996
• Gidman WK, Hassell K, Day J, Payne K. (2007). Does community pharmacy offer women family friendly working conditions and equal opportunities? The accounts of female community pharmacists over the age of 30. The International Journal of Pharmacy Practice, 15, 53-59. eScholarID:1d15519
• McAllister MM, Davies L, Payne K, Nicholls SSG, Donnai D, Macleod R. (2007). The emotional effects of genetic diseases: implications for clinical genetics. Am J Med Genet A, 143A( 22), 2651-61. eScholarID:1d17568
• McAllister MM, Payne K, Nicholls S, Macleod R, Donnai D, Davies LM. (2007). Improving Service Evaluation in Clinical Genetics: Identifying Effects of Genetic Diseases on Individuals and Families. J Genet Couns, Vol. 16(1), 71-83. eScholarID:1d15210
• Payne K, Newman WG, Fargher EA, Tricker K, Bruce IN, Ollier WER. (2007). TPMT testing in rheumatology: any better than routine monitoring? Rheumatology, 46, 727-729. eScholarID:1d15522
• Payne K, Nicholls SG, McAllister MM, Macleod R, Ellis I, Donnai D, Davies LM. (2007). Outcome measures for clinical genetics services: A comparison of genetics healthcare professionals and patients' views. Health Policy, doi: 10.1016/j.healthpol.2007.03.005, eScholarID:1d15913
• Seston E, Elliott R, Noyce P, Payne K. (2007). Women's preferences for the provision of emergency hormonal contraception services. Pharm World Sci, 29( 3), eScholarID:1d31665
• Seston EM, Elliott R.A, Noyce PR, Payne K. (2007). Women's preferences for the provision of emergency hormonal contraception services. Pharmacy World Science, 29, 183-189. eScholarID:1d27817

2006

• Brown TJ, Hooper L, Elliott RA, Payne K, Webb RT, Roberts C, Rostom A, Symmons D. (2006). A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technology Assessment, 10 (38), 1 - 202. eScholarID:1d17570
• Clemerson J, Payne K, Bissell P, Anderson C. (2006). Pharmacogenetics, the next challenge for pharmacy? Pharm World Sci, 28( 3), 126-30. eScholarID:1d30443
• Davies LM, Brown T, Haynes S, Payne K, Elliott R, McCollum C. (2006). Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess, 10( 44), eScholarID:1d30442
• Davies LM, Tamara Brown, Haynes S, Katherine Payne, Elliott RA, McCollum CN. (2006). Cost effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion. Health Technology Assessment. Health Technology Assessment, 10 (44), 1-228. eScholarID:1d13154
• Elliott RA, Hooper L, Payne K, Brown T, Roberts C, Symmons D. (2006). Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology (Oxford), 45( 5), eScholarID:1d13123
• Elliott RA, Hooper L, Payne K, Brown T, Roberts C, Symmons Deborah. (2006). Preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: are older strategies more cost effective in the general population? Rheumatology, 45, 603-613. eScholarID:1d26700
• Gemmell I, Heller R, Payne K, Edwards R, Roland M, Durrington P. (2006). Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Qual Saf Health Care, 15( 5), eScholarID:1d32133
• Gemmell IM, Heller RF, Payne K, Edwards R, Roland M, Durrington PN. (2006). The potential population impact of the UK Government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Quality and Safety in Health Care, eScholarID:1d27484
• McAllister MM, Payne K, Nicholls SSG, Macleod R, Donnai D, Davies LM. (2006). Improving service evaluation in clinical genetics: identifying effects of genetic diseases on individuals and families. Journal of Genetic Counselling, eScholarID:1d15517
• Payne K, Nicholls S, Marion McAllister, Macleod R, Middleton-Price HH, Donnai D, Davies LM. (2006). Towards outcome measures for clinicl agenetis services: a comparison of genetics healthcare professinals and patients' views. Journal Of Medical Genetics, 43 (supp 1), eScholarID:1d27976
• Payne K, Nicholls S, McAllister MM, Macleod R, Middleton-Price HH, Donnai D, Davies LM. (2006). Outcome measurement in clinical genetics services: a systematic review of validated measures. Journal Of Medical Genetics, 43 (supp 1), eScholarID:1d27975
• Payne K, Thornton JA. (2006). Interpreting economic evaluations for use in decision making. Eye News, 12(5), 18-22. eScholarID:1d15524
• Hughes D, Elliott RA, Payne K. (2006). Comments on NICE do not reflect expertise within the profession. The Pharmaceutical Journal, 277, 484. eScholarID:17d949

2005

• Elliott RA, Payne K. (2005). Essentials of economic evaluation in health care. eScholarID:4d212
• Gemmell I, Heller R, McElduff P, Payne K, Butler G, Edwards R, Roland M, Durrington PN. (2005). Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health, 59( 12), 1041-6. eScholarID:1d32463
• Gemmell IM, Heller RF, McElduff P, Payne K, Butler G, Edwards R, Roland M, Durrington PN. (2005). The population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. Journal Of Epidemiology And Community Health, 59, eScholarID:1d26697
• Payne K, Elliott RA. (2005). Using discrete choice experiments to value preferences for pharmacy services. International Journal Of Pharmacy Practice, 13, 9-20. eScholarID:1d28040
• Payne K, Fargher EA, Tricker K, Newman WG, Qasim FF, Poulton K, Andrews J, Houston JB, Elliott RA, Elles R, Ray DW, Shaffer JL, Griffiths CEM, Bruce IN, Roberts S A, Olier WER. (2005). Research Governance: What is reasonable protection? BMJ Rapid Response, eScholarID:17d957

2004

• Davies LM, Payne K, Marion McAllister, Nicholls SSG, Macleod R, Middleton-Price HH, Donnai D. (2004). Developing appropriate models of service delivery in clinical genetics. Journal Of Medical Genetics, 41: supplement 1, eScholarID:1d28046
• Elliott RA, Davies L, Payne K, Moore J, Harper N. (2004). Costing day case anesthesia: obtaining accurate patient-based costs for adults and children. Int J Technol Assess Health Care, 20( 4), 552-61. eScholarID:1d29511
• Elliott RA, Hooper L, Brown TJ, Payne K, Roberts C, Symmons D. (2004). Determining the relative cost-effectiveness of strategies for the prevention of NSAID-induced gastrointestinal toxicity using indirect comparison meta-analysis and probabilistic sensitivity analysis. Medical Decision Making 2004, 24(4), eScholarID:1d27974
• Gidman WK, Elliott R, Payne K. (2004). Using discrete choice experiments to elicit the importance of shared decision making to parents of children having day case surgery. Medical Decision Making 2004, 24(4), eScholarID:1d27973
• Hooper L, Brown TJ, Elliott RA, Payne K, Roberts C, Symmons D. (2004). The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. British Medical Journal, 329( 7472), 948-952. eScholarID:1d8993
• Marion McAllister, Payne K, Davies L, Nicholls SSG, Macleod R, Middleton-Price HH, Donnai D. (2004). How can we measure whether clinical genetic services are effective? Journal Of Medical Genetics, 41: supplement 1, eScholarID:1d28044
• Payne K, Elliott RA, Moore JK, Bennett J, Lawrence G. (2004). Day case anaesthesia: what would the patient prefer? Clinician in Management, 12(3), 133-139. eScholarID:1d28037
• Payne K, McAllister MM, Middleton-Price HH, Donnai D, Davies L. (2004). Using discrete choice experiments to value preferences for a clinical genetic service. Journal Of Medical Genetics, 41 (supp 1), eScholarID:1d27978

2003

• Elliott, RA, Payne, K, Moore J.K., Harper, N.J.N., St Leger, AS, Moore, E.W., Thoms, G, Pollard, BJ, McHugh, GA, Bennett, J., Lawrence, G., Kerr. J., Davies, LM. (2003). Clinical and economic choices in anaesthesia for day surgery: A prospective randomised controlled trial. Anaesthesia, 58, 412-421. eScholarID:1d24376 | DOI:10.1046/j.1365-2044.2003.03125.x
• Moore J, Moore E, Elliott RA, St Leger AS, Payne K, Kerr J. (2003). Propofol and halothane versus sevoflurane in paediatric day-case surgery: induction and recovery characteristics. Br J Anaesth, 90( 4), 461-466. eScholarID:1d13984
• Payne K, Davies LM, Noyce PR, Weiss M. (2003). The value of the managed entry of new drugs - A case study of Donepezil. International Journal of Technology Assessment in Health Care, 19( 1), 114-128. eScholarID:1d27306
• Payne K, Moore E, Elliott R, Moore J, McHugh G. (2003). Anaesthesia for day case surgery: a survey of paediatric clinical practice in the UK. Eur J Anaesthesiol, 20( 4), 325-30. eScholarID:1d31522
• Payne K, Moore E, Elliott R, Pollard B, McHugh G. (2003). Anaesthesia for day case surgery: a survey of adult clinical practice in the UK. Eur J Anaesthesiol, 20( 4), eScholarID:1d31961
• Payne K, Moore EW, Elliott RA, Moore JK, McHugh GA. (2003). Anaesthesia for day-case surgery: a survey of paediatric clinical practice in the UK. European Journal of Anaesthesiology, 20, eScholarID:1d23843
• Payne K, Moore EW, Elliott RA, Pollard BJ, McHugh GA. (2003). Anaesthesia for day-case surgery: a survey of adult clinical practice in the UK. European Journal of Anaesthesiology, 20, 311-324. eScholarID:1d23842

2002

• Elliott RA, Payne K, Davies LM, Moore J.K, Harper N.J.N, Moore E.W. (2002). A prospective patient specific cost analysis of alternative anaesthetic regimes in adult day case surgery. eScholarID:2d448
• Elliott RA, Payne K, Davies LM, Moore J.K, Moore E.W. (2002). Children's outcomes and parents' preferences for the induction and maintenance of anaesthesia for day-case surgery. eScholarID:2d821
• Elliott RA, Payne K, Davies LM, Moore JK, Moore EW. (2002). Patients' outcomes and preferences for the induction and maintenance of anaesthesia for day surgery. eScholarID:2d1644
• Moore E.W, Moore J.K, Kerr J, Elliott RA, Payne K. (2002). Comparison of anaesthetic regimes in adult day case surgery: Induction characteristics and recovery time. eScholarID:2d439
• Elliott, R, Payne, K, Moore, J, Davies, L, Harper, N, St Leger, A, Moore, E, Thoms, G, Pollard, BJ, McHugh, G, Bennett, J, Lawrence, G, Kerr, J. (2002). Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial. Health Technol Assess, 6( 30), eScholarID:1d17410
• Elliott, RA, Payne, K, Moore,J.K., Davies, LM, Harper,N.J., St Leger, AS, Moore,E.W., Thoms, G, Pollard, BJ, McHugh, GA, Bennett,J., Lawrence,G., Kerr,J. (2002). Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial. Health Technology Assessment, 6 (30), 1-264. eScholarID:1d5579

2001

• Elliott RA, Payne K, Davies L.M. (2001). Using contingent valuation in a RCT for induction and maintenance of anaesthetic agents for day case surgery. eScholarID:2d175
• Elliott RA, Payne K, Davies LM, Harper NJ. (2001). Using contingent valuation in a RCT for induction and maintenance of anaesthetic agents for day case surgery. eScholarID:2d1947
• Moore E.W, Moore J.K, Elliott RA, Payne K, Kerr J, Harper N.J.N. (2001). Propofol, sevoflurane and isoflurane: a comparision of early postoperative recovery in adult day case anaesthesia. eScholarID:2d595
• Moore E.W, Moore J.K, Kerr J, Elliott RA, Payne K. (2001). Recovery characteristics of propofol and halothane compared to sevoflurane in paediatric day case surgery. eScholarID:2d326
• Payne K, Elliott RA, Davies LM, Moore J.K, Moore E.W. (2001). A prospective patient specific cost analysis of propofol and halothane vs sevoflurane in paediatric day case surgery. eScholarID:2d1233
• Payne K, Elliott RA, Davies LM. (2001). Estimating the semi-fixed costs of a day case episode. eScholarID:2d594
• Payne K, Elliott RA, McHugh GA, Moore E. (2001). Variation in the management of PONV and pain in day case surgery: implications for evidence based practice. eScholarID:2d423
• Payne K, Noyce PR, Davies LM, Weiss M.C. (2001). Aspects of implementing a policy of 'managed entry' for new drugs. eScholarID:2d155

1998

• Payne K, Davies LM, Noyce PR, Weiss M.C. (1998). Introducing new drugs into the British NHS. eScholarID:2d174
• Payne K, Ryan-Woolley BM, Noyce PR. (1998). Role of Consumer attributes in predicting the impact of medicines deregulation on National Health Service prescribing in the United Kingdom. International Journal of Pharmacy Practice, 6, 150-158. eScholarID:1d698

1997

• Elliott RA, Payne K, Silcock J, King M. (1997). Health economics for LPC members. eScholarID:2d234
• Payne K, Ryan-Woolley BM, Noyce PR. (1997). Factors influencing consumers to purchase deregulated medicines over the counter. eScholarID:2d74
• Payne K, Weiss M.C, Claxton K, Noyce PR. (1997). Economic impact of decision-making and the introduction of new drugs in practice. eScholarID:2d166
• Elliott RA, Payne K, Silcock J. (1997). Evaluate primary care. Pharmacy in Practice, 405-418. eScholarID:1d384
• Elliott RA, Payne K, Silcock J. (1997). Prove the value of pharmacy. Pharmacy in Practice, 349-350. eScholarID:1d383
• Payne K, Silcock J, Elliott RA. (1997). Economics aids formulary choice. Pharmacy in Practice, 478-491. eScholarID:1d401
• Payne K, Elliott RA. (1997). Health economics for pharmacy undergraduates at Manchester. ISSEM Forum, eScholarID:17d57

1996

• Payne K, Ryan-Woolley BM, Noyce PR. (1996). The use of deregulated medicines: consumer perspectives. eScholarID:2d8
• Ryan-Woolley BM, Payne K. (1996). Deregulation: over to the consumer?. eScholarID:2d657
• Elliott RA, Payne K, Silcock J. (1996). Health Economics: Do or be done by. Pharmaceutical Journal, 257, eScholarID:1d576
• Payne K, Kozma C, Lawrence B. (1996). Comparing DHE and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. Pharmacoeconomics, 10, 59-71. eScholarID:1d566
• Payne K, Ryan-Woolley BM, Noyce PR. (1996). Is willingness to pay an indicator in determining the impact of deregulation on NHS prescribing? Health Economist's Study Group meeting proceedings, eScholarID:1d32687
• Payne K, Ryan-Woolley BM, Noyce PR. The impact of deregulation: a study of consumer decision-making and willingness-to-pay, Final Report for the Department of Health and European Commission. 1996. 0. eScholarID:19d35

• Gidman WK, Hassell K, Day J, Payne K. The impact of increasing workloads and role expansion on female community pharmacists in the UK. Research in Social and Administrative Pharmacy - in press, eScholarID:1d15520
• Payne K. Payne K, Nicholls S, McAllister M, MacLeod R, Donnai D, Davies LM. Outcome measurement in clinical genetics services: a systematic review of validated measures. Value in Health [in press]. eScholarID:19d350